Effect And Clinical Value Of Ambroxol On The Transportation Of Vancomycin Into Pulmonary

Objective: To explore the effect of ambroxol on the transportation of vancomycin into pulmonary, and evaluate clinical significance of the influence in antibacterial therapy.Methods: Sixty-nine patients with lower respiratory tract infection caused by MRSA or Gram-postive bacterium were randomly divided into two groups. Patients in control group (group A, n=34) treated with vancomycin; Patients in trial group (group B, n=35) treated with ambroxol combined vancomycin. No difference in other basic treatments. The concentration of vancomycin was tested from the serum and sputum before the fourth drug dose. Days were noted when fulfilled the course of treatments. Scores of pulmonary infection were marked and effective rates of treatments were evaluated on the first day, the fourth day, the seventh day and the last day of treating-course. Adverse effects were observed during the phase. The t test and X~2 test were used to analyze the results.Results: The mean vancomycin concentration in sputum of group B was significantly higher than group A (t test, p<0.05), but no significantly difference in serum between the two group. The course of treatments of group A was longer than group B (t test, p>0.05). After 72 hours of the treatments, the mean reducing-value of clinical pulmonary infection score in group B was better than in group A (t test, p<0.05),the mean score of group A was higher than group B (t test, p<0.05), no significantly difference of the two values at other observing-points. The total effective rate of therapy was greater than 80%, group B was greater than group A at the seventh drug day (X2 test, p<0.05), no significantly difference at other observing-schedules.Conclusion: The high effective rate of using vancomycin in treating pulmonary infection caused by MRSA is sure. Amboxol can incentive the transportation of vancomycin into pulmonary and promote the drug concentration of sputum. Compare with the program of vancomycin single use, the program of vancomycin combined with amboxol can shorten the vancomycin drug days, provide a swifter effect in pulmonary infection scores and raise the effective rates of anti-infection therapy.